Apr 22,2022

Clinical Outcomes Solutions and Carevive Systems Partner to Improve the Patient Experience in Cancer Care

Clinical Outcomes Solutions today announced a collaborative partnership with Carevive Systems, the leading oncology-focused health technology company. The two organizations, both deeply experienced with the collection and analysis of oncology data, are proud to announce that Carevive is joining the Oncology Outcomes initiative, launched in February 2019, to deliver world-class data and analysis to improve the patient experience and enhance survival outcomes of cancer patients. The partnership will leverage Carevive’s innovative digital oncology platform to capture the patient experience while on treatment, and COS’ deep experience in analyzing these types of data, providing invaluable insights for life science companies and regulatory authorities.

COLLABORATION PARTNERSHIP

#r&d

#rwd

#rpm

View Analyst & Ambassador Comments
Go to original news
Apr 23,2021

A Technology-Based Physical Activity Intervention for Patients With Metastatic Breast Cancer (Fit2ThriveMB): Protocol for a Randomized Controlled Trial

Increased incidence and life expectancy have resulted in a growing population of patients with metastatic breast cancer, and these patients experience high rates of morbidity and premature mortality. Increased physical activity (PA) is consistently associated with improved health and disease outcomes among early-stage survivors. However, there is a paucity of research on PA in patients with metastatic breast cancer, and existing PA interventions have exhibited low feasibility because of their focus on intense PA and/or requirement of on-site visits. Mobile health (mHealth)–based PA interventions may be particularly useful for patients with metastatic breast cancer because they allow for remote monitoring, which facilitates individual tailoring of PA recommendations to patients’ abilities and may minimize participant burden. However, no studies have examined mHealth PA interventions in patients with metastatic breast cancer.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 16,2021

Siemens Healthineers Completes Acquisition of Varian, Strengthening its Position as a Holistic Partner in Healthcare

Siemens Healthineers AG (Frankfurt: SHL) announced that it has successfully completed the acquisition of Varian Medical Systems, Inc. ("Varian"). The acquisition was previously announced on August 2, 2020. "With the completion of this transaction, we are now best-positioned to take two leaps together: a leap in cancer care and a leap in our impact on healthcare overall. Together, we are establishing a strong and trusted partner capable of supporting customers and patients along the entire cancer care continuum as well as through all major clinical pathways," said Dr. Bernd Montag, CEO of Siemens Healthineers AG.

COLLABORATION MERGERS & ACQUISITION

#product & service

View Analyst & Ambassador Comments
Go to original news
Apr 16,2021

Molecular Diagnostics Market by Product & Service, Application, Technology and End-user - Global Forecast to 2026

The global molecular diagnostics market size is projected to reach USD 31.8 billion by 2026 from USD 17.8 billion in 2021, at a CAGR of 12.3% during the forecast period. In 2020, the oncology testing segment accounted for the highest growth rate. Increasing incidence of cancer, technological advancements, and development of personalized medicine and companion diagnostic assays are the major factors driving this segment's growth.

View Analyst & Ambassador Comments
Go to original news
Apr 23,2021

Illumina’s oncology assay to move into blood-based cancers

Illumina inked a deal with Kartos Therapeutics to co-develop a companion diagnostic for the biotech’s KRT-232, an oral inhibitor that helps spur on tumor-suppressing proteins in cancers with certain mutations. Following the launch of multiple tumor diagnostic partnerships with Big Pharma earlier this year for its TruSight Oncology 500 assay, Illumina now aims to expand the use of its genomic profiling test to blood-based cancers.

COLLABORATION PARTNERSHIP

#product & service

#cdx

View Analyst & Ambassador Comments
Go to original news
Apr 26,2021

Development of the Exercise in Cancer Evaluation and Decision Support (EXCEEDS) algorithm

In this article, the researchers define the levels of exercise/rehabilitation services, provide a conceptual model to improve understanding of individual needs, and describe the development of the Exercise in Cancer Evaluation and Decision Support (EXCEEDS) algorithm.

CLINICAL STUDY

#ml

View Analyst & Ambassador Comments
Go to original news
Apr 27,2021

Voluntis and Eisai to collaborate on digital therapeutics for oncology patients

Voluntis today announced a collaboration agreement with Eisai to design and develop innovative digital therapeutics (DTx) to support patients treated for cancer as well as a strategic investment from Eisai in Voluntis.

COLLABORATION PARTNERSHIP

#r&d

#dtx

View Analyst & Ambassador Comments
Go to original news
Apr 29,2021

Working Together to Improve Outcomes: Applying Lessons from Oncology Collaborations to the COVID-19 Pandemic

The need for collaboration is particularly true in cancer research. In 2018, COTA joined nine other data partners, the FDA, and the National Cancer Institute in the Pilot 2.0 project, an initiative designed to leverage real-world endpoints to answer important clinical questions in advanced non-small cell lung cancer while establishing best practices for the use of RWD. This collaboration, building on the first Friends’ pilot project, has helped to push the RWD industry towards standardization, while enhancing the visibility and value of real-world evidence (RWE) to provide valuable insights in oncology.

View Analyst & Ambassador Comments
Go to original news
May 19,2021

Vinehealth and University of Surrey awarded £1m grant to trial a support app for patients undergoing cancer treatment

Vinehealth is delighted to announce their partnership with the University of Surrey in securing a £1 million Innovate UK grant to undertake a randomised controlled trial of our cancer companion app.

FUNDING GRANT
View Analyst & Ambassador Comments
Go to original news
May 20,2021

The Vinehealth Cancer Platform receives medical device CE mark certification

Vinehealth has received a Class 1 Medical Device CE mark for its Vinehealth mobile app for cancer patients and VinehealthPRO web application for clinicians. Vinehealth conforms to the requirements of the Medical Devices Directive 93/42/EEC. The Directive outlines safety and performance requirements for medical devices in the UK & EU.

REGULATORY CE MARK

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY